Literature DB >> 25787775

Expression of mucin 1 possessing a 3'-sulfated core1 in recurrent and metastatic breast cancer.

Hiroko Ideo1,2, Yuji Hinoda3, Kohei Sakai3, Ikue Hoshi1, Shigeru Yamamoto4, Masaaki Oka4, Kazunari Maeda4, Noriko Maeda4, Shoichi Hazama4, Junko Amano2, Katsuko Yamashita1.   

Abstract

Breast cancer is the most frequent cancer threatening the lives of women between the ages of 30 and 64. The cancer antigen 15-3 assay (CA15-3) has been widely used for the detection of breast cancer recurrence; however, its sensitivity and specificity are inadequate. We previously found that the breast cancer cell line YMBS secretes mucin 1 possessing 3'-sulfated core1 (3Score1-MUC1) into the medium. Therefore, we here evaluated whether 3Score1-MUC1 is secreted into the blood streams of breast cancer patients, and whether it can serve as an improved breast cancer marker. We developed a lectin-sandwich immunoassay, called Gal4/MUC1, using a 3'-sulfated core1-specific galectin-4 and a MUC1 monoclonal antibody. Using the Gal4/MUC1 assay method, we found that 3Score1-MUC1 was profoundly expressed in the blood streams of patients with recurrent and/or metastatic breast cancer. The positive ratio of the Gal4/MUC1 assay was higher than that of the CA15-3 assay in both primary (n = 240) and relapsed (n = 43) patients, especially in the latter of which the positive ratio of Gal4/MUC1 was 86%. whereas that of CA15-3 was 47%. Furthermore, serum Gal4/MUC1 levels could more sensitively reflect the recurrence of primary breast cancer patients after surgery. Therefore, the Gal4/MUC1 assay should be an excellent alternative to the CA15-3 tumor marker for tracking the recurrence and metastasis of breast cancer.
© 2015 UICC.

Entities:  

Keywords:  3′-sulfated core1; MUC1; breast cancer; galectin-4; metastasis; tumor marker

Mesh:

Substances:

Year:  2015        PMID: 25787775     DOI: 10.1002/ijc.29520

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  A new marker for breast cancer diagnosis, human epididymis protein 4: A preliminary study.

Authors:  Umut Riza Gündüz; Meral Gunaldi; Nilgun Isiksacan; Seyda Gündüz; Yildiz Okuturlar; Hakan Kocoglu
Journal:  Mol Clin Oncol       Date:  2016-06-03

Review 2.  The emerging role of galectins in high-fatality cancers.

Authors:  Cherylane Dubé-Delarosbil; Yves St-Pierre
Journal:  Cell Mol Life Sci       Date:  2017-11-08       Impact factor: 9.261

3.  Investigation of acidic free-glycans in urine and their alteration in cancer.

Authors:  Ken Hanzawa; Miki Tanaka-Okamoto; Hiroko Murakami; Mikio Mukai; Hidenori Takahashi; Takeshi Omori; Kenji Ikezawa; Kazuyoshi Ohkawa; Masayuki Ohue; Yasuhide Miyamoto
Journal:  Glycobiology       Date:  2021-05-03       Impact factor: 4.313

4.  Long Non-Coding RNA A2M-AS1 Promotes Breast Cancer Progression by Sponging microRNA-146b to Upregulate MUC19.

Authors:  Yuncong Liu; Qi Zhang; Jing Wu; Hanqun Zhang; Xin Li; Zhaopeng Zheng; Min Luo; Libo Li; Yang Xiang; Feiyue Yang; Li Wu
Journal:  Int J Gen Med       Date:  2020-11-27

5.  Serum Human Epididymis Protein-4 (HE4) - A novel Approach to Differentiate Malignant Frombenign Breast Tumors.

Authors:  K S S Sai Baba; Mohd Abdul Rehman; J Pradeep Kumar; Maira Fatima; G S N Raju; Shantveer G Uppin; Noorjahan Mohammed
Journal:  Asian Pac J Cancer Prev       Date:  2021-08-01

6.  Diagnostic potential of nanoparticle aided assays for MUC16 and MUC1 glycovariants in ovarian cancer.

Authors:  Shruti Jain; Nimrah Nadeem; Benjamin Ulfenborg; Maria Mäkelä; Shamima Afrin Ruma; Joonas Terävä; Kaisa Huhtinen; Janne Leivo; Björg Kristjansdottir; Kim Pettersson; Karin Sundfeldt; Kamlesh Gidwani
Journal:  Int J Cancer       Date:  2022-05-25       Impact factor: 7.316

7.  Antibody-Guided In Vivo Imaging for Early Detection of Mammary Gland Tumors.

Authors:  Laura Jeffords Moore; Lopamudra Das Roy; Ru Zhou; Priyanka Grover; Shu-Ta Wu; Jennifer M Curry; Lloye M Dillon; Priya M Puri; Mahboubeh Yazdanifar; Rahul Puri; Pinku Mukherjee; Didier Dréau
Journal:  Transl Oncol       Date:  2016-08       Impact factor: 4.243

8.  Expression of Tumour-Associated MUC1 Is a Poor Prognostic Marker in Breast Cancer in Kumasi, Ghana.

Authors:  E Atta Manu; K Bedu-Addo; N A Titiloye; C Ameh-Mensah; F Opoku; B M Duduyemi
Journal:  J Oncol       Date:  2020-04-22       Impact factor: 4.375

Review 9.  Electrochemical Nanobiosensors for Detection of Breast Cancer Biomarkers.

Authors:  Veronika Gajdosova; Lenka Lorencova; Peter Kasak; Jan Tkac
Journal:  Sensors (Basel)       Date:  2020-07-20       Impact factor: 3.576

10.  3'-Sulfo-TF Antigen Determined by GAL3ST2/ST3GAL1 Is Essential for Antitumor Activity of Fungal Galectin AAL/AAGL.

Authors:  Yang Li; Yan Li; Jing Xia; Qing Yang; Yijie Chen; Hui Sun
Journal:  ACS Omega       Date:  2021-07-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.